Back to Search
Start Over
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
- Source :
-
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2013 Feb; Vol. 11 (2), pp. 193-5. Date of Electronic Publication: 2012 Nov 14. - Publication Year :
- 2013
-
Abstract
- For patients treated with telaprevir, peginterferon, and ribavirin, futility rules have been developed to prevent needless drug exposure and minimize development of drug-resistant variants for patients who have little or no chance of achieving a sustained virologic response. We performed retrospective analyses of data from phase 3 trials and validated the current futility rule. All therapy should be stopped for treatment-naive and treatment-experienced patients if hepatitis C virus RNA levels are greater than 1000 IU/mL at weeks 4 or 12, or if hepatitis C virus RNA is detectable at week 24.<br /> (Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Clinical Trials, Phase III as Topic
Drug Therapy, Combination methods
Humans
Interferons therapeutic use
RNA, Viral blood
Retrospective Studies
Ribavirin therapeutic use
Viral Load
Antiviral Agents therapeutic use
Hepatitis C, Chronic drug therapy
Medical Futility
Oligopeptides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1542-7714
- Volume :
- 11
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
- Publication Type :
- Academic Journal
- Accession number :
- 23159528
- Full Text :
- https://doi.org/10.1016/j.cgh.2012.10.045